Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Epstein & White Financial LLC
Epstein & White Financial LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 17.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,006 shares of the biopharmaceutical company’s stock after selling 1,478 shares during the period. Epstein & White Financial LLC’s holdings in Pfizer were worth $261,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the company. Corbett Road Capital Management LLC purchased a new position in shares of Pfizer during the second quarter valued at $25,000. Reitz Capital Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth about $29,000. Rocky Mountain Advisers LLC grew its stake in Pfizer by 847.5% during the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,000 shares in the last quarter. Disciplined Investments LLC increased its holdings in shares of Pfizer by 43.3% in the 1st quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 347 shares during the period. Finally, JJJ Advisors Inc. purchased a new stake in shares of Pfizer in the second quarter worth approximately $44,000. 69.08% of the stock is owned by institutional investors and hedge funds.
Several research firms have weighed in on PFE. Berenberg Bank began coverage on shares of Pfizer in a research note on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price objective on the stock. UBS Group upped their price target on shares of Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. ValuEngine cut Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Mizuho reaffirmed a “buy” rating and issued a $43.00 target price on shares of Pfizer in a research report on Tuesday, September 15th. Finally, Morgan Stanley raised their price target on Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $39.64.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.64 by $0.14. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The company had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same quarter last year, the company posted $0.80 earnings per share. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, November 6th will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 4.01%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio is 51.53%.
In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the stock in a transaction dated Thursday, August 6th. The shares were bought at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $154,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.08% of the stock is owned by corporate insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.